OTC Statins: What We Have Is A Failure To Communicate
This article was originally published in The Tan Sheet
The immediate prospects for an OTC statin may have been dampened by the lopsided Mevacor panel vote, but persistent enthusiasm among core decision-makers offers optimism in the long term
You may also be interested in...
Two key presentations by FDA reviewers of Mevacor OTC study data may have undermined any chances of J&J/Merck's salvaging a favorable recommendation to switch the drug